GB2456237B8 - Stable adenosine receptor mutants - Google Patents

Stable adenosine receptor mutants

Info

Publication number
GB2456237B8
GB2456237B8 GB0901111A GB0901111A GB2456237B8 GB 2456237 B8 GB2456237 B8 GB 2456237B8 GB 0901111 A GB0901111 A GB 0901111A GB 0901111 A GB0901111 A GB 0901111A GB 2456237 B8 GB2456237 B8 GB 2456237B8
Authority
GB
United Kingdom
Prior art keywords
gpcr
ligand
mutants
binding
adenosine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB0901111A
Other languages
English (en)
Other versions
GB0901111D0 (en
GB2456237A (en
GB2456237B (en
Inventor
Antony Johannes Warne
Christopher Gordon Tate
Francesca Magnani
Malcolm Peter Weir
Maria Josefa Serrano-Vega
Richard Henderson
Yoko Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0705450A external-priority patent/GB0705450D0/en
Priority claimed from GB0724052A external-priority patent/GB0724052D0/en
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GB0901111A priority Critical patent/GB2456237B8/en
Publication of GB0901111D0 publication Critical patent/GB0901111D0/en
Publication of GB2456237A publication Critical patent/GB2456237A/en
Application granted granted Critical
Publication of GB2456237B publication Critical patent/GB2456237B/en
Publication of GB2456237B8 publication Critical patent/GB2456237B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
GB0901111A 2007-03-22 2008-03-20 Stable adenosine receptor mutants Active GB2456237B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0901111A GB2456237B8 (en) 2007-03-22 2008-03-20 Stable adenosine receptor mutants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0705450A GB0705450D0 (en) 2007-03-22 2007-03-22 Mutant proteins and method for selecting them
GB0724052A GB0724052D0 (en) 2007-12-08 2007-12-08 Mutant proteins and methods for selecting them
GB0805267A GB2447786C (en) 2007-03-22 2008-03-20 Mutant G-protein coupled receptor proteins and methods for selecting them
GB0901111A GB2456237B8 (en) 2007-03-22 2008-03-20 Stable adenosine receptor mutants

Publications (4)

Publication Number Publication Date
GB0901111D0 GB0901111D0 (en) 2009-03-11
GB2456237A GB2456237A (en) 2009-07-15
GB2456237B GB2456237B (en) 2009-10-28
GB2456237B8 true GB2456237B8 (en) 2009-12-09

Family

ID=39386585

Family Applications (4)

Application Number Title Priority Date Filing Date
GB0805267A Active GB2447786C (en) 2007-03-22 2008-03-20 Mutant G-protein coupled receptor proteins and methods for selecting them
GB0901111A Active GB2456237B8 (en) 2007-03-22 2008-03-20 Stable adenosine receptor mutants
GB0901110A Active GB2456236B8 (en) 2007-03-22 2008-03-20 Stable muscarinic receptor mutants
GB0901095A Active GB2456235B8 (en) 2007-03-22 2008-03-20 Stable beta-adrenergic receptor mutants

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0805267A Active GB2447786C (en) 2007-03-22 2008-03-20 Mutant G-protein coupled receptor proteins and methods for selecting them

Family Applications After (2)

Application Number Title Priority Date Filing Date
GB0901110A Active GB2456236B8 (en) 2007-03-22 2008-03-20 Stable muscarinic receptor mutants
GB0901095A Active GB2456235B8 (en) 2007-03-22 2008-03-20 Stable beta-adrenergic receptor mutants

Country Status (14)

Country Link
US (7) US8785135B2 (pl)
EP (4) EP3926045A1 (pl)
JP (6) JP4842400B2 (pl)
CN (2) CN103641908A (pl)
AT (1) ATE544854T1 (pl)
AU (1) AU2008228085B2 (pl)
CA (1) CA2681415C (pl)
DK (1) DK2121919T3 (pl)
ES (1) ES2381780T3 (pl)
GB (4) GB2447786C (pl)
HR (1) HRP20120336T1 (pl)
PL (1) PL2121919T3 (pl)
PT (1) PT2121919E (pl)
WO (1) WO2008114020A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3926045A1 (en) 2007-03-22 2021-12-22 Heptares Therapeutics Limited Mutant proteins and methods for selecting them
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) * 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
DE08718604T1 (de) * 2008-03-05 2009-12-24 Medical Research Council Kristallstruktur
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
US8900591B2 (en) 2010-08-20 2014-12-02 Heptares Therapeutics Limited Vaccines comprising mutant GPCRs with increased conformational stability relative to parent receptors
US20140031525A1 (en) * 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
WO2012116203A1 (en) 2011-02-23 2012-08-30 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
JP6251252B2 (ja) * 2012-06-01 2017-12-20 ヘプタレス セラピューティックス リミテッド アッセイ
JP6443344B2 (ja) 2013-01-30 2018-12-26 フエー・イー・ベー・フエー・ゼツト・ウエー スクリーニングおよび薬物開発のための新規キメラポリペプチド
EP2970425B1 (en) 2013-03-15 2019-10-30 United Kingdom Research and Innovation Mutant membrane proteins and methods for their production
WO2014176524A2 (en) 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
WO2014176544A1 (en) * 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Water soluble g-protein coupled receptor
CA2914831C (en) 2013-06-11 2022-10-11 Paul Scherrer Institut Method for determining mutateable ligand-gpcr binding at single amino acid resolution and pairs of mutated ligand and gpcr
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
CN104151401A (zh) * 2014-06-05 2014-11-19 维亚生物科技(上海)有限公司 融合表达离子通道蛋白及运输蛋白的方法及其使用的蛋白片断
GB2527286A (en) 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
US10287349B2 (en) 2014-10-31 2019-05-14 Abilita Bio, Inc. Modified membrane spanning proteins and methods for the preparation and use thereof
JP6722951B2 (ja) 2015-07-31 2020-07-15 国立研究開発法人理化学研究所 膜タンパク質の製造方法およびその利用
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
EP3205450A1 (de) * 2016-02-09 2017-08-16 Hermes Schleifkörper GmbH Verfahren zur herstellung eines keramischen formkörpers
CN109415445A (zh) 2016-05-04 2019-03-01 阿比利塔生物公司 用于制备多跨膜蛋白的方法和平台
CN109553687B (zh) * 2017-09-27 2021-07-06 北京大学 基于g蛋白偶联受体构建的荧光探针
CN114038498B (zh) * 2022-01-06 2022-03-18 北京晶泰科技有限公司 Gpcr的热稳定性突变预测方法、结构筛选方法及其装置

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
JP3147916B2 (ja) 1991-03-08 2001-03-19 森永製菓株式会社 体外免疫方法
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
EP0644935A1 (en) * 1992-06-12 1995-03-29 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
EP0763202A4 (en) 1994-05-23 1998-12-09 Smithkline Beecham Corp ENCODED COMBINATORIAL LIBRARIES
US20020028443A1 (en) 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
WO1997035881A2 (en) 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
CA2250975A1 (en) 1996-04-15 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
JP2002510505A (ja) 1998-04-03 2002-04-09 フィロス インク. 位置特定可能な蛋白質アレイ
EP1070257A2 (en) 1998-04-06 2001-01-24 Lerner Pharmaceuticals, Inc. Directed evolution biosensors
US6692696B1 (en) 1998-06-18 2004-02-17 ARETé ASSOCIATES Biosensor
WO2000012705A2 (en) * 1998-09-01 2000-03-09 Basf Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US7094593B1 (en) 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
WO2000070343A2 (en) 1999-05-14 2000-11-23 Repliscent, Inc. G-protein coupled receptor based biosensors and sense replication systems
EP1242448A2 (en) * 1999-11-17 2002-09-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
AU2001243145A1 (en) 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US7678539B2 (en) 2000-08-10 2010-03-16 Corning Incorporated Arrays of biological membranes and methods and use thereof
WO2002018590A2 (en) 2000-08-30 2002-03-07 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6448377B1 (en) 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
CA2425149A1 (en) 2000-10-26 2002-08-01 New England Medical Center Hospitals, Inc. Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
US20030232331A1 (en) 2000-12-05 2003-12-18 Casman Stacie J. Novel proteins and nucleic acids encoding same
JP2005503124A (ja) * 2001-02-14 2005-02-03 アムジェン インコーポレイテッド Gタンパク質共役受容体分子及びその使用
CA2439383A1 (en) * 2001-02-26 2002-09-06 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US7208279B2 (en) 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US20070010948A1 (en) 2001-03-30 2007-01-11 Masaji Ishiguro G protein-coupled receptor structural model and a method of designing ligand binding to g protein-coupled receptor by using the structural model
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US20050009204A1 (en) 2003-07-11 2005-01-13 Ye Fang Multiplexed binding assays for receptor arrays
ATE340190T1 (de) 2001-10-25 2006-10-15 Astex Therapeutics Ltd Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung
US7115377B2 (en) 2001-10-26 2006-10-03 Atto Bioscience, Inc. Cell-based assays for G-protein-coupled receptor-mediated activities
AU2003227268A1 (en) 2002-03-28 2003-10-13 Takeda Chemical Industries, Ltd. Novel screening method
JP2004238384A (ja) * 2002-03-28 2004-08-26 Takeda Chem Ind Ltd 新規スクリーニング方法
CA2483701A1 (en) * 2002-04-24 2003-11-06 Banyu Pharmaceutical Co., Ltd. Constitutively active histamine h3 receptor mutants and uses thereof
ES2340475T3 (es) 2002-05-01 2010-06-04 Vertex Pharmaceuticals Incorporated Estructura cristalizada de proteina aurora-2 y sus bolsillos de union.
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
US20040096914A1 (en) 2002-11-20 2004-05-20 Ye Fang Substrates with stable surface chemistry for biological membrane arrays and methods for fabricating thereof
AU2004241193B2 (en) * 2003-05-20 2011-03-10 The University Court Of The University Of Glasgow Materials and methods relating to G-protein coupled receptor oligomers
US7745161B2 (en) 2003-12-19 2010-06-29 Palo Alto Research Center Incorporated Amplification of enzymatic reactions for use with an enthalpy array
US20060281699A1 (en) 2004-05-12 2006-12-14 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
US20060188964A1 (en) 2004-07-28 2006-08-24 Filippo Mancia Processing for producing and crystallizing G-protein coupled receptors
JP2006340717A (ja) * 2005-05-11 2006-12-21 Sekisui Chem Co Ltd Gタンパク質共役型受容体に対する結合性評価方法及び評価用組成物、融合タンパク質、並びに、遺伝子
FR2890174B1 (fr) 2005-08-30 2009-04-24 Cis Bio Internat Sa Procede pour la mise en evidence d'un processus biologique par mesure d'un fret
US20070154947A1 (en) 2005-08-31 2007-07-05 The Trustees Of Princeton University Chemical biodiscriminator
EP1948232A4 (en) 2005-11-18 2010-09-22 Univ Ohio State Res Found VIRAL GENE PRODUCTS AND VACCINATION METHODS FOR PREVENTING ASSOCIATED VIRAL DISEASES
US7495024B2 (en) * 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
EP3926045A1 (en) * 2007-03-22 2021-12-22 Heptares Therapeutics Limited Mutant proteins and methods for selecting them
WO2009051769A1 (en) 2007-10-17 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for crystallizing g protein-coupled receptors
JP5560448B2 (ja) 2007-10-22 2014-07-30 ザ スクリプス リサーチ インスティテュート 膜タンパク質の高分解能結晶を得るための方法および組成物
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
DE08718604T1 (de) 2008-03-05 2009-12-24 Medical Research Council Kristallstruktur
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
US8900591B2 (en) 2010-08-20 2014-12-02 Heptares Therapeutics Limited Vaccines comprising mutant GPCRs with increased conformational stability relative to parent receptors
WO2012030735A1 (en) 2010-08-30 2012-03-08 Confometrx, Inc. Method and composition for crystallizing a family c gpcr
US20140031525A1 (en) 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
US20120288913A1 (en) 2011-05-13 2012-11-15 The Scripps Research Institute Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
WO2013142278A1 (en) 2012-03-22 2013-09-26 New York University Plasmodium vivax vaccine compositions
JP6251252B2 (ja) 2012-06-01 2017-12-20 ヘプタレス セラピューティックス リミテッド アッセイ
WO2014028644A1 (en) 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
US20150261911A1 (en) 2014-03-13 2015-09-17 Heptares Therapeutics Limited Crystal structure

Also Published As

Publication number Publication date
GB0901111D0 (en) 2009-03-11
US11673938B2 (en) 2023-06-13
US20240052017A1 (en) 2024-02-15
ATE544854T1 (de) 2012-02-15
JP2018164456A (ja) 2018-10-25
US20190241644A1 (en) 2019-08-08
GB0901110D0 (en) 2009-03-11
CN101688203B (zh) 2013-12-11
GB2456236B (en) 2009-10-28
EP3926045A1 (en) 2021-12-22
JP2010521983A (ja) 2010-07-01
DK2121919T3 (da) 2012-05-21
US20210061882A1 (en) 2021-03-04
JP2016187348A (ja) 2016-11-04
JP2021036901A (ja) 2021-03-11
EP2121919B1 (en) 2012-02-08
HRP20120336T1 (hr) 2012-05-31
GB2456237A (en) 2009-07-15
PL2121919T3 (pl) 2012-07-31
US20100190188A1 (en) 2010-07-29
US20180086814A1 (en) 2018-03-29
GB2456235A (en) 2009-07-15
WO2008114020A9 (en) 2010-03-11
CA2681415A1 (en) 2008-09-25
JP7419217B2 (ja) 2024-01-22
GB2447786A (en) 2008-09-24
GB2447786C (en) 2011-11-09
CN101688203A (zh) 2010-03-31
US20120270230A1 (en) 2012-10-25
GB0901095D0 (en) 2009-03-11
AU2008228085A1 (en) 2008-09-25
US20160052991A1 (en) 2016-02-25
AU2008228085B2 (en) 2011-12-08
CA2681415C (en) 2020-11-03
JP2014155502A (ja) 2014-08-28
PT2121919E (pt) 2012-05-17
GB2447786B (en) 2009-11-11
ES2381780T3 (es) 2012-05-31
GB2456236B8 (en) 2009-12-09
US8785135B2 (en) 2014-07-22
GB2456237B (en) 2009-10-28
EP2386635A2 (en) 2011-11-16
GB0805267D0 (en) 2008-04-30
JP2011224018A (ja) 2011-11-10
GB2456235B8 (en) 2009-12-09
GB2456236A (en) 2009-07-15
WO2008114020A2 (en) 2008-09-25
JP4842400B2 (ja) 2011-12-21
JP6426661B2 (ja) 2018-11-21
EP2121919A2 (en) 2009-11-25
GB2456235B (en) 2009-10-28
EP2386635A3 (en) 2012-02-08
EP2450445A1 (en) 2012-05-09
WO2008114020A3 (en) 2009-03-19
CN103641908A (zh) 2014-03-19

Similar Documents

Publication Publication Date Title
GB2456237B8 (en) Stable adenosine receptor mutants
WO2009081136A3 (en) Screening
WO2009071914A3 (en) Mutant proteins and methods for producing them
WO2007082144A3 (en) B7-h1 and survivin in cancer
WO2009073664A3 (en) Rating raters
WO2008109878A3 (en) Testing device
SG144146A1 (en) Adenosine receptor agonists
EP2068544A4 (en) VOICE MIXING METHOD, MULTIPOINT CONFERENCE SERVER USING THE METHOD AND PROGRAM
WO2010075084A3 (en) User interface tools
WO2009026189A3 (en) Methods and apparatus for providing location data with variable validity and quality
EP2310844A4 (en) Systems and methods for determining geologic properties using acoustic analysis
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ATE544870T1 (de) Profilierung einer rezeptorfamilie
TW200634624A (en) System, apparatus and method of selecting graphical component types at runtime
WO2009018359A3 (en) Selecting and applying a communication version
WO2006015084A3 (en) Compositions, kits and assays containing reagents directed to cortactin and an arg/abl protein kinase
WO2011092504A3 (en) Biomarkers for schizophrenia
WO2010040003A3 (en) Human a2a adenosine receptor crystals and uses thereof
WO2007132359A3 (en) Composition containing lactobacillus sp. and a cannabinoid receptor and/or a opioid receptor agonist
WO2007047686A3 (en) Brochure creation internet system
WO2007101116A3 (en) Glur2 receptor modulators
WO2006104761A3 (en) Unique sequence hybridization probes (usp)
TW200700727A (en) Screen
O'Dale BUILDING PRIVATE AND PUBLIC SECTOR SUPPORT FOR SPACE RESOURCE USE
Ghic USING DIFFERENT ELECTRE METHODS IN MULTICRITERIAL DECISIONS

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20090924 AND 20090930